Medtronic scoffs at St. Jude Medical's claims that its Enlightn renal denervation system lowers blood pressure faster than Medtronic's Symplicity, calling them "interesting" but merely "hypothesis-generating."
By Merrill Goozner
Much has been written about the travails of the pharmaceutical industry. Generic competition is reducing profitability as leading blockbuster drugs like Pfizer's Lipitor lose patent protection. Biotech generic competition is on the horizon.
Disappearing stent technology makes waves at this year's EuroPCR conference in Paris, with Elixir Medial touting its fully bioabsorbable coronary scaffold and Terumo and Biotronik unveiling results for their stents with a bioerodable polymer coatings.
Disappearing technology had a strong presence at this year's EuroPCR conference in Paris, with rival device makers demonstrating the safety and efficacy of their next-generation stents.
Elixir Medical unveiled 1st-in-man clinical results for its DESolve fully bioabsorbable drug-eluting scaffold system, a stent made from a proprietary polymer and coated in novolimus. The entire stent is designed to be absorbed by the body in 1-2 years.
St. Jude Medical's newly CE Marked Enlightn renal denervation system boasts twice the reduction in blood pressure after 1 month compared with rival technologies.
St. Jude Medical's (NYSE:STJ) newly cleared Enlightn renal denervation system lowered patients' blood pressure by twice as much as rival systems in the same amount of time, according to a new study.
Preliminary findings from a study of the Enlightn system found that patients with hypertension saw a 28 point reduction in blood pressure after 30 days.
Transcatheter aortic valve implantation proves successful in reinforcing failed valve prosthetics, but researchers warn against making it a common practice.
Although patients may benefit from having a failed aortic valve prosthetic reinforced via transcatheter aortic valve implantation, researchers warned against making the procedure a common practice.
Medtronic touts new clearances for its Resolute Integrity stent and clinical findings for its In.Pact balloons and hints of more studies to be revealed later this week at the EuroPCR conference in Paris.
Medical device titan Medtronic (NYSE:MDT) touted a string of new indications for its Resolute Integrity drug-eluting stents at this year's EuroPCR meeting in Paris.
With new clearances in hand, the Resolute Integrity stent is now the DES with the broadest range of indications in Europe and the only DES on the market with indication for treating bifurcated lesions, according to a press release.
A rare but deadly genetic mutation that prevents the body from absorbing protein can be set off by weight loss surgery.
MASSDEVICE ON CALL — A rare genetic mutation that killed a weight loss surgery patient in Tennessee can be set off by weight loss surgeries like gastric bypass.
The disease, which causes the body to convert protein into ammonia, also causes the body to consume lean muscle when protein isn't eaten, creating a cruel cycle of spiking ammonia levels in the blood and anorexia-like weight loss.
